After Major Oncology Conference, All Eyes Turn to Industry Innovation

USA News Group News Commentary

Issued on behalf of Oncolytics Biotech Inc.

VANCOUVER, BC, June 12, 2025 /CNW/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For investors, there have been several oncology innovators and healthcare providers with recent developments to pay attention to, including Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC.TO), Tempest Therapeutics, Inc. (NASDAQ:TPST), Citius Oncology, Inc. (NASDAQ:CTOR), Citius Pharmaceuticals, Inc. (NASDAQ:CTXR), and Cardinal Health (NYSE:CAH).